Roche Holding's second-quarter results revealed a slower-than-expected recovery for its blockbuster eye drug Vabysmo, holding back overall sales growth. The Swiss pharmaceutical giant reported that the ophthalmology treatment, which had been projected to rebound strongly this year, continues to face headwinds in key markets.

Investors had been counting on Vabysmo to drive the next phase of Roche's expansion, particularly as older franchises face biosimilar competition. The drug's underperformance raises questions about the timeline for Roche's growth re-acceleration, with analysts revising near-term forecasts.

Management emphasized that the fundamentals supporting Vabysmo's long-term potential remain intact, citing ongoing clinical data and pipeline progress. However, the market's focus has shifted to a key new drug candidate that could power the next growth cycle, though its commercial impact remains years away.

The results underscore the challenges of launching complex ophthalmology treatments in competitive markets, where dosing regimens and reimbursement dynamics can slow adoption curves.